In addition to connected devices, the exhibition featured a variety of new conventional inhalers and nebulizers. After the announcement of its collaboration with Hovione, H&T Presspart showed off the Hovione-developed PowdAir Plus capsule based DPI, and Chinese device company Well-Bridge exhibited its hand-held MeBreez nebulizer.
Well-Bridge was one of several Chinese companies exhibiting for the first time at RDD Europe 2017; another was Wuxi-based CMO CF PharmTech, whose management includes Cirrus Pharmaceuticals co-founder Jean-Marc Bovet.Other first time exhibitors included specialty packaging company CSP Technologies, contract research company IDD-Xpert, inhaler prototyping company Zenius, Indian device manufacturer Newtec, and SRF Limited, which acquired the Dymel brand of HFA 134a from DuPont in 2015.
Several exhibitors represented reconfigured and/or renamed companies. Device maker RPC Formatec shared a table with Plastiape, which it apparently acquired quietly in 2016. Newly formed Munit combines the services of particle reduction companies Jetpharma and Microchem.
Catalent’s table display noted “New commercial manufacturing for pMDI,” apparently a reference to the expansion of its inhaler manufacturing capabilities that was announced in 2013, which was to include a new pMDI filling line from Coster.
Other exhibitors at RDD 2017 included Astech Projects, Capsugel, CD-adapco, Copley Scientific, Next Breath, Pharmaserve NW, and Team Consulting